Condition
Neurogenic Urinary Bladder
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT01598103Phase 2TerminatedPrimary
Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions
NCT00549939Phase 3CompletedPrimary
Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction
Showing all 2 trials